Overview

Perioperative Pregabalin Use, Rehabilitation, Pain Outcomes and Anxiety Following Hip Surgery

Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
0
Participant gender:
All
Summary
Pain prior to surgery is of particular concern in patients undergoing total hip arthroplasty (THA) since it is the most important predictor of pain and poor function 2-3 years after surgery. Previous studies have investigated various treatments for managing pain during and after surgery. However, no study has investigated the short and long term effects of pregabalin in terms of functional rehabilitation, pain outcome and anxiety following total hip arthroplasty. Therefore, the aim of the present study is determine if the following: (1) if perioperative pregabalin administration positively influence early rehabilitation and recovery of physical function and to determine if these effects maintained at 6 weeks and 3 months post surgery. (2) To determine if perioperative pregabalin administration reduce postoperative movement evoked pain associated with rehabilitation and if these effects also maintained at 6 weeks and 3 months post surgery.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborator:
Pfizer
Treatments:
Pregabalin
Criteria
Inclusion Criteria:

- Provision of informed consent, American Society of Anesthesiologists physical status
I-III, VAS > 5, age18-75 years, male or female, scheduled for THA.

Exclusion Criteria:

Patients will not be enrolled in this study for the following reasons:

- Patients not providing informed consent.

- Known allergy to any of the medications being used.

- History of drug or alcohol abuse.

- Patients with chronic pain on slow-release preparations of opioid.

- Patients with Rheumatoid Arthritis.

- Patients with psychiatric disorders.

- Patients unable or unwilling to use Patient Controlled Analgesia. (PCA)

- Diabetic patients or those with impaired renal function (Creatinine >106).

- Obese patients (i.e. BMI > 40).